32,305 Shares in AtriCure, Inc. (NASDAQ:ATRC) Bought by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the 4th quarter, Holdings Channel.com reports. The fund purchased 32,305 shares of the medical device company’s stock, valued at approximately $1,153,000.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in AtriCure by 0.9% in the third quarter. Vanguard Group Inc. now owns 4,689,883 shares of the medical device company’s stock valued at $205,417,000 after acquiring an additional 43,431 shares during the period. TimesSquare Capital Management LLC raised its holdings in shares of AtriCure by 39.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 904,835 shares of the medical device company’s stock worth $39,632,000 after buying an additional 254,655 shares in the last quarter. Fiera Capital Corp raised its holdings in shares of AtriCure by 2.2% in the 3rd quarter. Fiera Capital Corp now owns 688,057 shares of the medical device company’s stock worth $30,137,000 after buying an additional 14,624 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of AtriCure by 3.0% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 495,473 shares of the medical device company’s stock worth $21,702,000 after buying an additional 14,199 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in AtriCure by 3.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 362,986 shares of the medical device company’s stock valued at $15,899,000 after buying an additional 11,779 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. StockNews.com lowered AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Stifel Nicolaus cut their price target on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a report on Friday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of AtriCure in a research note on Wednesday, April 10th. UBS Group lifted their target price on shares of AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Finally, Oppenheimer raised AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 target price on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and a consensus target price of $52.63.

AtriCure Price Performance

Shares of NASDAQ ATRC traded down $0.44 during trading on Thursday, reaching $22.61. The company had a trading volume of 326,838 shares, compared to its average volume of 677,749. AtriCure, Inc. has a 52 week low of $22.07 and a 52 week high of $59.61. The business’s 50 day moving average price is $30.02 and its 200-day moving average price is $33.77. The stock has a market cap of $1.09 billion, a PE ratio of -34.26 and a beta of 1.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.66 and a current ratio of 3.57.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $106.50 million during the quarter, compared to analysts’ expectations of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. AtriCure’s revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) EPS. Analysts expect that AtriCure, Inc. will post -0.71 earnings per share for the current year.

Insider Activity

In related news, insider Karl S. Dahlquist sold 8,231 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $37.36, for a total value of $307,510.16. Following the transaction, the insider now owns 52,839 shares in the company, valued at $1,974,065.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the sale, the insider now owns 74,284 shares in the company, valued at approximately $2,727,708.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Karl S. Dahlquist sold 8,231 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total value of $307,510.16. Following the completion of the transaction, the insider now directly owns 52,839 shares in the company, valued at approximately $1,974,065.04. The disclosure for this sale can be found here. Insiders have sold 13,116 shares of company stock valued at $468,797 over the last 90 days. 3.20% of the stock is owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.